DelveInsight Report Analyzes Factor XI Inhibitor Pipeline

Market research firm DelveInsight has published its "Factor XI Inhibitors – Pipeline Insight, 2026" report, offering a comprehensive analysis of the development of Factor XI (FXI) inhibitors. The report covers over eight companies and eight pipeline drugs, examining their progress through clinical and non-clinical stages.

FXI is a key factor in blood coagulation, and its inhibitors have garnered attention as novel anticoagulants aimed at reducing thrombosis risk by targeting the intrinsic pathway of the coagulation cascade. Unlike previous anticoagulants that focus on the common pathway, FXI inhibitors may offer a new approach to preventing blood clots with a potentially lower risk of bleeding.

The report provides detailed profiles of individual development programs, including Ionis Pharmaceuticals' fesomersen (IONIS-FXI-LRx), an antisense medicine designed to reduce FXI production, which has benefited from a collaboration with Bayer. Another notable candidate is Aronora, Inc.'s AB023 (xisomab 3G3), a monoclonal antibody that specifically inhibits FXI activation. The analysis includes assessments of clinical and non-clinical studies for these and other compounds across various development phases.

DelveInsight's analysis assesses the current state of the field, identifying challenges and opportunities in FXI inhibitor research and development. It details drug mechanisms of action, clinical trial data, collaborations, and recent news, providing valuable insights for stakeholders in the pharmaceutical and biotechnology sectors.